- Home
- PCQ vs SNY Comparison
PCQ vs SNY Comparison
Compare PCQ & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- SNY
- Stock Information
- Founded
- PCQ 2001
- SNY 1994
- Country
- PCQ United States
- SNY France
- Employees
- PCQ N/A
- SNY N/A
- Industry
- PCQ Investment Managers
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- PCQ Finance
- SNY Health Care
- Exchange
- PCQ Nasdaq
- SNY Nasdaq
- Market Cap
- PCQ N/A
- SNY 123.6B
- IPO Year
- PCQ N/A
- SNY N/A
- Fundamental
- Price
- PCQ $8.71
- SNY $49.90
- Analyst Decision
- PCQ
- SNY Buy
- Analyst Count
- PCQ 0
- SNY 2
- Target Price
- PCQ N/A
- SNY $62.50
- AVG Volume (30 Days)
- PCQ 69.6K
- SNY 3.1M
- Earning Date
- PCQ 01-01-0001
- SNY 04-24-2025
- Dividend Yield
- PCQ 4.63%
- SNY 3.21%
- EPS Growth
- PCQ N/A
- SNY 39.56
- EPS
- PCQ N/A
- SNY 5.45
- Revenue
- PCQ N/A
- SNY $48,817,552,946.00
- Revenue This Year
- PCQ N/A
- SNY $5.35
- Revenue Next Year
- PCQ N/A
- SNY $6.69
- P/E Ratio
- PCQ N/A
- SNY $18.73
- Revenue Growth
- PCQ N/A
- SNY N/A
- 52 Week Low
- PCQ $8.19
- SNY $45.80
- 52 Week High
- PCQ $10.50
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- PCQ 55.31
- SNY 37.47
- Support Level
- PCQ $8.65
- SNY $51.67
- Resistance Level
- PCQ $8.80
- SNY $55.73
- Average True Range (ATR)
- PCQ 0.10
- SNY 0.89
- MACD
- PCQ 0.05
- SNY -0.12
- Stochastic Oscillator
- PCQ 85.00
- SNY 0.34
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.